Qingbin Cui

2.3k total citations · 2 hit papers
49 papers, 1.8k citations indexed

About

Qingbin Cui is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Qingbin Cui has authored 49 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 22 papers in Molecular Biology and 9 papers in Cancer Research. Recurrent topics in Qingbin Cui's work include Drug Transport and Resistance Mechanisms (19 papers), Cancer therapeutics and mechanisms (9 papers) and HIV/AIDS drug development and treatment (8 papers). Qingbin Cui is often cited by papers focused on Drug Transport and Resistance Mechanisms (19 papers), Cancer therapeutics and mechanisms (9 papers) and HIV/AIDS drug development and treatment (8 papers). Qingbin Cui collaborates with scholars based in China, United States and Israel. Qingbin Cui's co-authors include Zhe‐Sheng Chen, Jing‐Quan Wang, Yehuda G. Assaraf, Charles R. Ashby, Dong‐Hua Yang, Liuya Wei, Pranav Gupta, Chao‐Yun Cai, Liang Ren and Yuqi Yang and has published in prestigious journals such as SHILAP Revista de lepidopterología, Pharmacological Reviews and International Journal of Molecular Sciences.

In The Last Decade

Qingbin Cui

43 papers receiving 1.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Modulating ROS to overcome multidrug resistance in cancer

2018 545 citations Qingbin Cui, Jing‐Quan Wang et al. Drug Resistance Updates profile →
Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance

2021 171 citations Jing‐Quan Wang, Yuqi Yang et al. Drug Resistance Updates profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Qingbin Cui	1.0k	679	285	229	185	49	1.8k
Kristen M. Pluchino	1.0k 1.0×	1.1k 1.7×	293 1.0×	180 0.8×	160 0.9×	14	2.0k
Tina S. Homayouni	999 1.0×	430 0.6×	223 0.8×	310 1.4×	153 0.8×	4	1.9k
Narges Baluch	1.1k 1.0×	475 0.7×	236 0.8×	333 1.5×	163 0.9×	17	2.2k
Qiu‐Xu Teng	932 0.9×	964 1.4×	261 0.9×	73 0.3×	163 0.9×	50	1.6k
Feifei Xu	1.2k 1.1×	362 0.5×	352 1.2×	157 0.7×	132 0.7×	76	1.8k
Zi‐Ning Lei	1.2k 1.2×	1.2k 1.8×	306 1.1×	78 0.3×	192 1.0×	72	2.2k
Christophe Blanquart	1.6k 1.5×	503 0.7×	376 1.3×	149 0.7×	346 1.9×	80	2.9k
Karol Bukowski	678 0.7×	370 0.5×	227 0.8×	210 0.9×	110 0.6×	16	1.3k
Valentina De Falco	1.3k 1.2×	892 1.3×	274 1.0×	218 1.0×	192 1.0×	40	2.6k
Angelica M. Merlot	1.0k 1.0×	631 0.9×	185 0.6×	136 0.6×	249 1.3×	24	2.2k

Countries citing papers authored by Qingbin Cui

Since Specialization

Citations

This map shows the geographic impact of Qingbin Cui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qingbin Cui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qingbin Cui more than expected).

Fields of papers citing papers by Qingbin Cui

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Qingbin Cui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qingbin Cui. The network helps show where Qingbin Cui may publish in the future.

Co-authorship network of co-authors of Qingbin Cui

This figure shows the co-authorship network connecting the top 25 collaborators of Qingbin Cui. A scholar is included among the top collaborators of Qingbin Cui based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Qingbin Cui. Qingbin Cui is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Mingjuan, et al.. (2025). Repurposing dimethyl fumarate for cancer therapy: current evidence and future directions. Frontiers in Pharmacology. 16. 1721876–1721876.

Cui, Qingbin, et al.. (2025). Design, synthesis, and evaluation of quinoxaline-based survivin inhibitors for castration-resistant prostate cancer. Bioorganic Chemistry. 163. 108714–108714.

Cui, Qingbin, et al.. (2025). Targeting fatty acid synthase to overcome PARP inhibitor resistance and to create an artificial synthetic lethality for triple-negative breast cancer. Genes & Diseases. 13(1). 101817–101817. 1 indexed citations

Cui, Qingbin, et al.. (2025). Targeting fatty acid synthase for cancer drug discovery: Retrospective analyses and outlook. Pharmacological Reviews. 78(1). 100105–100105.

Cui, Qingbin, Wenwen Ding, Bingling Luo, et al.. (2024). Novel gold-based complex GC7 suppresses cancer cell proliferation via impacting energy metabolism mediated by mitochondria. Bioorganic & Medicinal Chemistry. 112. 117897–117897. 4 indexed citations

Liu, Zhi‐Jie, Baojian Guo, Qingbin Cui, et al.. (2024). Pharmacological Mechanisms of Periplocae Cortex Against Congestive Heart Failure Based on Network Pharmacology and Experimental Evaluation. Natural Product Communications. 19(3).

Gao, Hailing, Qingbin Cui, Jing‐Quan Wang, et al.. (2023). The AKT inhibitor, MK-2206, attenuates ABCG2-mediated drug resistance in lung and colon cancer cells. Frontiers in Pharmacology. 14. 1235285–1235285. 16 indexed citations

Ding, Wenwen, Qingbin Cui, Wenhua Lu, et al.. (2023). Synthesis and biological evaluation of novel bi-gold mitocans in lung cancer cells. Frontiers in Chemistry. 11. 1292115–1292115. 3 indexed citations

Narayanan, Silpa, Jing‐Quan Wang, Zhuo‐Xun Wu, et al.. (2021). The Novel Benzamide Derivative, VKNG-2, Restores the Efficacy of Chemotherapeutic Drugs in Colon Cancer Cell Lines by Inhibiting the ABCG2 Transporter. International Journal of Molecular Sciences. 22(5). 2463–2463. 13 indexed citations

10.

Wang, Jing‐Quan, Yuqi Yang, Chao‐Yun Cai, et al.. (2021). Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance. Drug Resistance Updates. 54. 100743–100743. 171 indexed citations breakdown →

11.

Wang, Jing‐Quan, Qiu‐Xu Teng, Zi‐Ning Lei, et al.. (2020). Venetoclax, a BCL-2 Inhibitor, Enhances the Efficacy of Chemotherapeutic Agents in Wild-Type ABCG2-Overexpression-Mediated MDR Cancer Cells. Cancers. 12(2). 466–466. 48 indexed citations

12.

Yang, Yuqi, Ning Ji, Chao‐Yun Cai, et al.. (2020). Modulating the function of ABCB1: in vitro and in vivo characterization of sitravatinib, a tyrosine kinase inhibitor. Cancer Communications. 40(7). 285–300. 31 indexed citations

13.

Ma, Shijie, Zizheng Dong, Qingbin Cui, Jingyuan Liu, & Jian‐Ting Zhang. (2020). eIF3i regulation of protein synthesis, cell proliferation, cell cycle progression, and tumorigenesis. Cancer Letters. 500. 11–20. 13 indexed citations

14.

Wang, Jing‐Quan, Qiu‐Xu Teng, Zi‐Ning Lei, et al.. (2020). Reversal of Cancer Multidrug Resistance (MDR) Mediated by ATP-Binding Cassette Transporter G2 (ABCG2) by AZ-628, a RAF Kinase Inhibitor. Frontiers in Cell and Developmental Biology. 8. 601400–601400. 26 indexed citations

15.

Gao, Hailing, Pranav Gupta, Qingbin Cui, et al.. (2020). Sapitinib Reverses Anticancer Drug Resistance in Colon Cancer Cells Overexpressing the ABCB1 Transporter. Frontiers in Oncology. 10. 574861–574861. 24 indexed citations

16.

Cui, Qingbin, Chao‐Yun Cai, Jing‐Quan Wang, et al.. (2019). Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells. International Journal of Molecular Sciences. 20(17). 4095–4095. 26 indexed citations

17.

Fan, Yingfang, Wei Zhang, Leli Zeng, et al.. (2018). Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters. Cancer Letters. 421. 186–198. 96 indexed citations

18.

Cui, Qingbin, et al.. (2017). Synthesis and Preliminary Evaluation of Danshensutetramethylpyrazine Derivatives. Journal of Pharmaceutical and Biomedical Sciences. 7(5).

19.

Wang, Liang, Xiaojing Zhang, Judy Yuet‐Wa Chan, et al.. (2015). A Novel Danshensu Derivative Prevents Cardiac Dysfunction and Improves the Chemotherapeutic Efficacy of Doxorubicin in Breast Cancer Cells. Journal of Cellular Biochemistry. 117(1). 94–105. 32 indexed citations

20.

Batson, Robert G., Daniel S Turner, Paul S. Ray, et al.. (2009). Work Zone Lane Closure Analysis Model. Molecular Genetics and Metabolism. 111(3). 399–403. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact